{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:07:10Z","timestamp":1784542030143,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["203326"],"award-info":[{"award-number":["203326"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.coi.2026.102741","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:33:57Z","timestamp":1771421637000},"page":"102741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evolution and prospects for the definition of clinically useful endpoints in Sj\u00f6gren disease"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-093X","authenticated-orcid":false,"given":"Maxime","family":"Beydon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-9948","authenticated-orcid":false,"given":"Simon J","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-1856","authenticated-orcid":false,"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102741_bib1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102741_bib2","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1136\/annrheumdis-2016-210758","article-title":"Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sj\u00f6gren\u2019s syndrome with other sets of criteria in Japanese patients","volume":"76","author":"Tsuboi","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.2024-1012","article-title":"A systematic review of clinical trial designs and outcome measures in Sj\u00f6gren disease randomized controlled trials","volume":"52","author":"Beydon","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib4","first-page":"2225","article-title":"Selection of study endpoints and patients for clinical trials in primary Sj\u00f6gren\u2019s syndrome","volume":"40","author":"Arends","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren\u2019s syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sj\u00f6gren\u2019s disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2026.102741_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152385","article-title":"Identification of outcome domains in primary Sj\u00f6gren\u2019s disease: a scoping review by the OMERACT Sj\u00f6gren disease working group","volume":"65","author":"Nguyen","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102741_bib10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled trial of remicade in primary Sj\u00f6gren\u2019s syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102741_bib11","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102741_bib12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102741_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2026.102741_bib14","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2026.102741_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3899\/jrheum.210633","article-title":"PROMIS provides a broader overview of health-related quality of life than the ESSPRI in evaluation of Sj\u00f6gren syndrome","volume":"49","author":"DiRenzo","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/s42358-021-00181-9","article-title":"Pain and fatigue are predictors of quality of life in primary Sj\u00f6gren\u2019s syndrome","volume":"61","author":"Dias","year":"2021","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib18","first-page":"1896","article-title":"Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients","volume":"31","author":"Wolfe","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004526","article-title":"Development of a web-based ecological momentary assessment tool to measure day-to-day variability of the symptoms in patients with Sj\u00f6gren\u2019s disease","volume":"10","author":"Georgel","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102741_bib20","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40744-022-00489-y","article-title":"Content\u00a0validity of Sj\u00f6gren\u2019s syndrome symptom diary and functional assessment of chronic illness therapy-fatigue in patients with Sj\u00f6gren\u2019s","volume":"9","author":"Griffiths","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coi.2026.102741_bib21","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.ard.2025.05.004","volume":"84","author":"Bowman","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40744-022-00489-y","article-title":"Content validity of Sj\u00f6gren\u2019s syndrome symptom diary and functional assessment of chronic illness therapy-fatigue in patients with Sj\u00f6gren\u2019s","volume":"9","author":"Griffiths","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coi.2026.102741_sbref23","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St. Clair","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2026.102741_sbref24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102741_bib25","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_sbref26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.coi.2026.102741_sbref27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib28","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib29","unstructured":"Novartis:\u00a0Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sj\u00f6gren\u2019s disease. Disponible sur: \u3008https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease\u3009 [cit\u00e9 30 sept 2025]."},{"key":"10.1016\/j.coi.2026.102741_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren\u2019s syndrome treated with rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_bib32","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/acr.21991","article-title":"European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Disease Activity Index and European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Patient-Reported Index: a complete picture of primary Sj\u00f6gren\u2019s syndrome patients","volume":"65","author":"Seror","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102741_bib33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/art.42238","article-title":"Symptom-based cluster analysis categorizes Sj\u00f6gren\u2019s disease subtypes: an international cohort study highlighting disease severity and treatment discordance","volume":"74","author":"McCoy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib34","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_sbref34","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2026.102741_bib37","series-title":"Arthritis & Rheumatology","first-page":"5344","article-title":"Transcriptomic stratification predicts response to rituximab, abatacept or the association of hydroxychloroquine and leflunomide in 3 randomized controlled clinical trials in Sjogren\u2019s disease","author":"Chevet","year":"2024"},{"key":"10.1016\/j.coi.2026.102741_bib38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.43096","article-title":"Distinct pathophysiologic pathways support stratification of Sj\u00f6gren\u2019s disease based on symptoms, clinical, and routine biological data","volume":"77","author":"Nguyen","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_sbref38","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_sbref39","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/annrheumdis-2015-208504","article-title":"Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102741_sbref41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102741_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of Sj\u00f6gren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib44","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2665-9913(24)00183-8","article-title":"Identification and evolution of predictors of Sj\u00f6gren\u2019s disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study","volume":"6","author":"Goules","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102741_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102062","article-title":"Mortality risk factors in primary Sj\u00f6gren syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.coi.2026.102741_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002955","article-title":"Impact of patient ancestry on heterogeneity of Sj\u00f6gren\u2019s disease","volume":"9","author":"Beydon","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102741_bib47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diii.2024.01.003","article-title":"Lung fibrosis is uncommon in primary Sj\u00f6gren\u2019s disease: a retrospective analysis of computed tomography features in 77 patients","volume":"105","author":"de Fr\u00e9mont","year":"2024","journal-title":"Diagn Inter Imaging"},{"key":"10.1016\/j.coi.2026.102741_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2026.102741_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002721","article-title":"Development and testing of an alternative responder definition for EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI)","volume":"9","author":"Wratten","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102741_bib50","unstructured":"The Sjogren Tool for Assessing Response (STAR): Assessment of response rates overall, according to baseline activity and by domain: reanalysis of 9 clinical trials in primary Sjogren syndrome. ACR Meeting Abstracts. [cit\u00e9 17 Oct 2025]. Disponible sur: \u3008https:\/\/acrabstracts.org\/abstract\/the-sjogren-tool-for-assessing-response-star-assessment-of-response-rates-overall-according-to-baseline-activity-and-by-domain-reanalysis-of-9-clinical-trials-in-primary-sjogren-syndrome\/\u3009."},{"key":"10.1016\/j.coi.2026.102741_bib51","unstructured":"Seror R, Baron G, Cornec D, Perrodeau E, Camus M, Bowman S, et al: The Sjogren\u2019s Tool for Assessing Response (Star): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren\u2019s Syndrome; 2022."},{"key":"10.1016\/j.coi.2026.102741_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000634","article-title":"Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria","volume":"9","author":"van Vollenhoven","year":"2022","journal-title":"Lupus Sci Med"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152600018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152600018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:35:45Z","timestamp":1784540145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279152600018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"alternative-id":["S095279152600018X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102741","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution and prospects for the definition of clinically useful endpoints in Sj\u00f6gren disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102741"}}